Biomarkers in the Setting of Benign Prostatic Hyperplasia-induced Lower Urinary Tract Symptoms: What an Interventional Radiologist Needs to Know

Overview

Journal Br J Radiol

Publisher Oxford University Press

Specialty Radiology

Date 2020 Jul 25

PMID 32706988

Authors

Shamar Young

Alessandro Gasparetto

Hamed Jalaeian

Jafar Golzarian

Affiliations

Soon will be listed here.

Abstract

With increasing evidence to support prostate artery embolization (PAE) in the treatment of benign prostatic hyperplasia (BPH)-induced lower urinary tract symptoms (LUTS), Interventional Radiologists have begun to play an important role in the management of these patients. One area of knowledge needed when developing a PAE practice is knowledge of prostate-specific antigen (PSA) and other biomarkers utilized to detect prostate cancer in this population and what role they should play in the work up and follow-up of patients presenting with presumed BPH-induced LUTS. Furthermore, understanding how to evaluate presumed BPH-induced LUTS and stratify the risk of prostate cancer is an important skill to develop. The goal of this review is to provide Interventional Radiologists who have begun or aim to begin a PAE practice with the information they need to know regarding PSA levels and prostate cancer risk stratification for this patient population.

References

Bussemakers M, van Bokhoven A, Verhaegh G, Smit F, Karthaus H, Schalken J . DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59(23):5975-9. View

Carroll P, Parsons J, Andriole G, Bahnson R, Castle E, Catalona W . NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. J Natl Compr Canc Netw. 2016; 14(5):509-19. PMC: 10184498. DOI: 10.6004/jnccn.2016.0060. View

Mohler J, Antonarakis E, Armstrong A, DAmico A, Davis B, Dorff T . Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(5):479-505. DOI: 10.6004/jnccn.2019.0023. View

Telang J, Lane B, Cher M, Miller D, Dupree J . Prostate cancer family history and eligibility for active surveillance: a systematic review of the literature. BJU Int. 2017; 120(4):464-467. DOI: 10.1111/bju.13862. View

Dutruel S, Jeph S, Margolis D, Wehrli N . PI-RADS: what is new and how to use it. Abdom Radiol (NY). 2020; 45(12):3951-3960. DOI: 10.1007/s00261-020-02482-x. View

Wolf A, Wender R, Etzioni R, Thompson I, DAmico A, Volk R . American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010; 60(2):70-98. DOI: 10.3322/caac.20066. View

Pisco J, Bilhim T, Pinheiro L, Fernandes L, Pereira J, Costa N . Medium- and Long-Term Outcome of Prostate Artery Embolization for Patients with Benign Prostatic Hyperplasia: Results in 630 Patients. J Vasc Interv Radiol. 2016; 27(8):1115-22. DOI: 10.1016/j.jvir.2016.04.001. View

Ohigashi T, Kanao K, Mizuno R, Kikuchi E, Nakashima J, Oya M . Predicting the probability of significant prostate cancer in Japanese men with serum prostate-specific antigen less than 10 ng/mL: development of a novel pre-biopsy nomogram. Int J Urol. 2010; 17(3):274-80. DOI: 10.1111/j.1442-2042.2010.02453.x. View

Sokolova A, Cheng H . Genetic Testing in Prostate Cancer. Curr Oncol Rep. 2020; 22(1):5. PMC: 10832578. DOI: 10.1007/s11912-020-0863-6. View

10.

McKiernan J, Donovan M, ONeill V, Bentink S, Noerholm M, Belzer S . A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncol. 2016; 2(7):882-9. DOI: 10.1001/jamaoncol.2016.0097. View

11.

Littrup P, Kane R, Mettlin C, Murphy G, Lee F, Toi A . Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer. 1994; 74(12):3146-58. DOI: 10.1002/1097-0142(19941215)74:12<3146::aid-cncr2820741214>3.0.co;2-z. View

12.

Nichol M, Wu J, Huang J, Denham D, Frencher S, Jacobsen S . Cost-effectiveness of Prostate Health Index for prostate cancer detection. BJU Int. 2011; 110(3):353-62. DOI: 10.1111/j.1464-410X.2011.10751.x. View

13.

Catalona W, Partin A, Slawin K, Brawer M, Flanigan R, Patel A . Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279(19):1542-7. DOI: 10.1001/jama.279.19.1542. View

14.

Banerji J, Wolff E, Massman 3rd J, Odem-Davis K, Porter C, Corman J . Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening. J Urol. 2015; 195(1):66-73. DOI: 10.1016/j.juro.2015.07.099. View

15.

Ellison L, Cheli C, Bright S, Veltri R, Partin A . Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening. Urology. 2002; 60(4 Suppl 1):42-6. DOI: 10.1016/s0090-4295(02)01694-1. View

16.

Shen P, Zhao J, Sun G, Chen N, Zhang X, Gui H . The roles of prostate-specific antigen (PSA) density, prostate volume, and their zone-adjusted derivatives in predicting prostate cancer in patients with PSA less than 20.0 ng/mL. Andrology. 2017; 5(3):548-555. DOI: 10.1111/andr.12322. View

17.

Szeliski K, Adamowicz J, Gastecka A, Drewa T, Pokrywczynska M . Modern urology perspectives on prostate cancer biomarkers. Cent European J Urol. 2019; 71(4):420-426. PMC: 6338806. DOI: 10.5173/ceju.2018.1762. View

18.

Leyten G, Hessels D, Smit F, Jannink S, de Jong H, Melchers W . Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. Clin Cancer Res. 2015; 21(13):3061-70. DOI: 10.1158/1078-0432.CCR-14-3334. View

19.

Christensson A, LAURELL C, Lilja H . Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990; 194(3):755-63. DOI: 10.1111/j.1432-1033.1990.tb19466.x. View

20.

Wei J, Feng Z, Partin A, Brown E, Thompson I, Sokoll L . Can urinary PCA3 supplement PSA in the early detection of prostate cancer?. J Clin Oncol. 2014; 32(36):4066-72. PMC: 4265117. DOI: 10.1200/JCO.2013.52.8505. View